Lineage Cell Therapeutics (LCTX) Assets Average (2011 - 2026)

Lineage Cell Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $111.1 million for Q1 2026.

• On a quarterly basis, Assets Average fell 1.27% year-over-year to $111.1 million in Q1 2026; TTM through Mar 2026 was $111.1 million, a 1.27% decrease from a year earlier, with the FY2025 full-year figure at $112.9 million, up 5.4% from the prior year.
• Assets Average improved to $111.1 million in Q1 2026 per LCTX's latest filing, from $101.1 million in the prior quarter.
• Across five years, Assets Average topped out at $159.5 million in Q1 2022 and bottomed at $90.2 million in Q3 2025.
• The 5-year median for Assets Average is $108.9 million (2023), against an average of $113.8 million.
• Across the five-year window, Assets Average surged 35.27% in 2022 and decreased 25.76% in 2023, its largest moves.
• Year by year, Assets Average stood at $127.4 million in 2022, then retreated by 18.7% to $103.6 million in 2023, then climbed by 1.27% to $104.9 million in 2024, then fell by 3.62% to $101.1 million in 2025, then grew by 9.84% to $111.1 million in 2026.
• Per Business Quant, the three latest LCTX Assets Average figures stand at $111.1 million (Q1 2026), $101.1 million (Q4 2025), and $90.2 million (Q3 2025).